Kymera Therapeutics Inc (NASDAQ:KYMR) price on Friday, March 21, fall -2.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $32.54.
A look at the stock’s price movement, the close in the last trading session was $33.21, moving within a range at $32.08 and $33.9. The beta value (5-Year monthly) was 2.227. Turning to its 52-week performance, $53.27 and $29.07 were the 52-week high and 52-week low respectively. Overall, KYMR moved -13.04% over the past month.
Kymera Therapeutics Inc’s market cap currently stands at around $2.11 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests up to a 10.63% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 62.45M, representing a 32.67% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that KYMR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 5 recommend KYMR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
KYMR’s current price about -1.74% and -11.61% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.37, while 7-day volatility ratio is 4.97% and 6.67% in the 30-day chart. Further, Kymera Therapeutics Inc (KYMR) has a beta value of 2.14, and an average true range (ATR) of 1.99. Analysts have given the company’s stock an average 52-week price target of $55.5, forecast between a low of $54 and high of $57. Looking at the price targets, the low is -65.95% off current price level while to achieve the yearly target high, price needs to move -75.17%. Nonetheless, investors will most likely welcome a -70.56% jump to $55.5 which is the analysts’ median price.
If we refocus on Kymera Therapeutics Inc (NASDAQ:KYMR), historical trading data shows that trading volumes averaged 0.65 over the past 10 days and 564.58K over the past 3 months. The company’s latest data on shares outstanding shows there are 64.89 million shares.
The 16.91% of Kymera Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 95.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.58 million on 2025-02-28, giving us a short ratio of 12.81. The data shows that as of 2025-02-28 short interest in Kymera Therapeutics Inc (KYMR) stood at 1302.0000000000002 of shares outstanding, with shares short falling to 7.69 million registered in 2025-01-31. Current price change has pushed the stock -19.12% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the KYMR stock continues to rise going into the next quarter.
